These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11353527)

  • 1. Synthesis and biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the Tn epitope.
    Peri F; Cipolla L; Rescigno M; La Ferla B; Nicotra F
    Bioconjug Chem; 2001; 12(3):325-8. PubMed ID: 11353527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
    Lo-Man R; Vichier-Guerre S; Bay S; Dériaud E; Cantacuzène D; Leclerc C
    J Immunol; 2001 Feb; 166(4):2849-54. PubMed ID: 11160353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines.
    Cipolla L; Rescigno M; Leone A; Peri F; La Ferla B; Nicotra F
    Bioorg Med Chem; 2002 May; 10(5):1639-46. PubMed ID: 11886825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use.
    Vichier-Guerre S; Lo-Man R; BenMohamed L; Dériaud E; Kovats S; Leclerc C; Bay S
    J Pept Res; 2003 Sep; 62(3):117-24. PubMed ID: 12895273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust immune responses elicited by a fully synthetic three-component vaccine.
    Ingale S; Wolfert MA; Gaekwad J; Buskas T; Boons GJ
    Nat Chem Biol; 2007 Oct; 3(10):663-7. PubMed ID: 17767155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.
    Renaudet O; BenMohamed L; Dasgupta G; Bettahi I; Dumy P
    ChemMedChem; 2008 May; 3(5):737-41. PubMed ID: 18205167
    [No Abstract]   [Full Text] [Related]  

  • 8. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
    Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
    Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short synthetic glycopeptides successfully induce antibody responses to carcinoma-associated Tn antigen.
    Vichier-Guerre S; Lo-Man R; Bay S; Deriaud E; Nakada H; Leclerc C; Cantacuzène D
    J Pept Res; 2000 Feb; 55(2):173-80. PubMed ID: 10784033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
    Laubreton D; Bay S; Sedlik C; Artaud C; Ganneau C; Dériaud E; Viel S; Puaux AL; Amigorena S; Gérard C; Lo-Man R; Leclerc C
    Cancer Immunol Immunother; 2016 Mar; 65(3):315-25. PubMed ID: 26847142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen.
    Vichier-Guerre S; Lo-Man R; Huteau V; Dériaud E; Leclerc C; Bay S
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3567-70. PubMed ID: 15177475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines.
    Grigalevicius S; Chierici S; Renaudet O; Lo-Man R; Dériaud E; Leclerc C; Dumy P
    Bioconjug Chem; 2005; 16(5):1149-59. PubMed ID: 16173792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen.
    Buskas T; Ingale S; Boons GJ
    Angew Chem Int Ed Engl; 2005 Sep; 44(37):5985-8. PubMed ID: 16108081
    [No Abstract]   [Full Text] [Related]  

  • 16. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
    Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
    J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis.
    Jeon I; Lee D; Krauss IJ; Danishefsky SJ
    J Am Chem Soc; 2009 Oct; 131(40):14337-44. PubMed ID: 19746915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of tumor-associated glycopeptide antigens for the development of tumor-selective vaccines.
    Dziadek S; Kunz H
    Chem Rec; 2004; 3(6):308-21. PubMed ID: 14991920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.
    Xu Y; Sette A; Sidney J; Gendler SJ; Franco A
    Immunol Cell Biol; 2005 Aug; 83(4):440-8. PubMed ID: 16033540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.